Chronic Kidney Diseases, Sarcopenia
Conditions
Brief summary
The aim of this research study is to look at the body composition (such as muscle and fat) in people with chronic kidney disease (CKD) and comparing it with body composition is people without CKD. The investigators currently understand loss of muscle function and mass (sarcopenia) affect the general health of people as they age, but this process seems to be more common, accelerated, and occurs earlier in people with CKD. There is limited evidence in this area, and we believe that if we understand when and how sarcopenia affects people with CKD, investigators can guide future trials and treatments to help treat sarcopenia, and in turn improve quality of life and health outcomes in people with CKD.
Detailed description
In this study, the investigators will follow up people with CKD in two visits a year apart. In both visits, the investigators will measure the participants body composition and estimated kidney function using 2 different testing methods - Cystatin C eGFR and Creatinine eGFR. Using both the results in a formula, the creatinine muscle index can be calculated. If this index correlated with sarcopenia, it will be helpful tool in the care of people with CKD as will be a easy to use screening tool for sarcopenia in this population.
Interventions
DIAGNOSTIC_TESTCystatin C eGFR
Cystatin C eGFR is not used routinely currently in clinical practice in the UK. It involved a blood test to analyse Cystatin C.
OTHERBioimpedance Analysis (Body composition analysis)
Participants will stand on a bioimpedance analysis machine which will measure different components of body composition
Sponsors
University Hospitals of Derby and Burton NHS Foundation Trust
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Subjects capable of giving informed consent ≥18 years of age Chronic kidney disease stages 3-5 looked after in secondary care nephrology Healthy volunteers with normal kidney function (Control)
Exclusion criteria
* Pregnancy * Subjects with known neuromuscular diseases, e.g. myopathy, muscular dystrophy, muscular atrophy * Renal transplant recipients * Patients with pacemakers
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Creatinine Muscle Index (mg/day per 1.73m2) | Day 1 (day recruited) and at 1 year | Product of serum Creatinine and estimated glomerular filtration rate with Cystatin C (eGFRcys) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Skeletal muscle mass (kg) | At Day 1 (day recruited) and 1 year | Measured by Bioimpedance analysis |
| Multimorbidity Score | Day 1 (day recruited) and 1 year | The Cambridge Multimorbidity Score is a UK validated index to score the comorbidities of participants. One can score from 0 to 20 on this index. Higher scores are associated with worse clinical outcomes. |
Countries
United Kingdom
Outcome results
None listed